Basel, Switzerland

Daniel Zimmermann

USPTO Granted Patents = 8 

 

Average Co-Inventor Count = 7.8

ph-index = 3

Forward Citations = 22(Granted Patents)


Company Filing History:


Years Active: 2016-2025

Loading Chart...
Loading Chart...
8 patents (USPTO):

Title: The Innovative Contributions of Daniel Zimmermann

Introduction

Daniel Zimmermann is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of pharmaceuticals, holding a total of 8 patents. His work primarily focuses on the development of innovative compounds and formulations that have the potential to improve therapeutic outcomes.

Latest Patents

Among his latest patents is the invention of new crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide, commonly known as ribociclib. This patent includes pharmaceutical compositions that utilize these new crystalline forms, as well as methods of treatment and preparation. Another significant patent involves the preparation of a MEK inhibitor, detailing processes for creating crystallized compounds and their pharmaceutical applications.

Career Highlights

Daniel Zimmermann has worked with prominent companies in the pharmaceutical industry, including Array Biopharma Inc. and Novartis AG. His experience in these organizations has allowed him to contribute to the development of innovative therapies that address various medical needs.

Collaborations

Throughout his career, Zimmermann has collaborated with talented professionals, including Christoph Max Krell and Marian Misun. These partnerships have fostered a collaborative environment that enhances the innovation process.

Conclusion

Daniel Zimmermann's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a significant inventor. His work continues to influence the development of new therapeutic options, showcasing the importance of innovation in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…